Biogen, AbbVie to take multiple sclerosis drug off global market

Biogen Inc. and AbbVie Inc. said early Friday that the companies are voluntarily withdrawing their relapsing multiple sclerosis drug, Zinbryta, from global markets. Evaluating the drug's "complex and evolving benefit/risk profile... will not be possible going forward given the limited number of patients being treated," the companies said. The withdrawal is in patients' best interests, said Biogen Chief Medical Officer Alfred Sandrock. Zinbryta, which the companies said is generally used in...